{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:19:47Z","timestamp":1777681187269,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Discipline Boosting Program of Shanghai Fourth People\u2019s Hospital","award":["SY-XKZT-2020-1013"],"award-info":[{"award-number":["SY-XKZT-2020-1013"]}]},{"name":"Key Supported Clinical Specialties of Hongkou District Health Committee","award":["HKZK2020A06"],"award-info":[{"award-number":["HKZK2020A06"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81971042"],"award-info":[{"award-number":["81971042"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Three-Year Action Plan for Strengthening Public Health System in Shanghai Subject Chief Scientist","award":["GWV-10.2-XD05"],"award-info":[{"award-number":["GWV-10.2-XD05"]}]},{"name":"the Pilot Program of Naval Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To explore the effects of long-term oral ACEIs\/ARBs on the incidence of exacerbation and in-hospital mortality in elderly COVID-19 Omicron BA.2 patients with hypertension, especially patients aged 80 years or older.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>In this retrospective study, patients suffering mild and rcommon COVID-19 with hypertension who were hospitalized in the Shanghai Fourth People\u2019s Hospital between April 2022 and June 2022 were enrolled. Primary outcomes included the incidence of exacerbation and in-hospital mortality. Secondary outcomes included the incidence of respiratory failure of patients, use of mechanical ventilation, nucleic acid conversion time (NCT), hospitalization costs, and the temporal trend of the incidence of exacerbations and in-hospital mortality in different age groups. The data were analysed using propensity score weighting (PSW).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the entire cohort, there were 298 ACEI\/ARB users and 465 non-ACEI\/ARB users. The ACEI\/ARB group showed a lower incidence of exacerbation (OR\u2009=\u20090.64, 95% CI for OR: 0.46\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.0082) and lower in-hospital mortality (OR\u2009=\u20090.49, 95% CI for OR: 0.27\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.0201) after PSW. Sensitivity analysis obtained the same results. The results of the subgroup of patients aged 80 years and older obtained a similar conclusion as the whole cohort. Most of the study indicators did not differ statistically significantly in the subgroup of patients aged 60 to 79 years except for rates of mechanical ventilation and respiratory failure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Antihypertensive therapy with ACEIs\/ARBs might reduce the incidence of exacerbation and in-hospital mortality. The findings of this study support the use of ACEIs\/ARBs in COVID-19 patients infected by Omicron BA.2, especially in patients aged 80 years or older with hypertension.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08913-6","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T11:02:32Z","timestamp":1702897352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-term oral ACEI\/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhe","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lize","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"issue":"5","key":"8913_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s10096-020-04138-6","volume":"40","author":"S Beyerstedt","year":"2021","unstructured":"Beyerstedt S, Casaro EB, Rangel \u00c9B. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 Infection. Eur J Clin Microbiol Infect Dis. 2021;40(5):905\u201319. https:\/\/doi.org\/10.1007\/s10096-020-04138-6.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"7950","key":"8913_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41586-022-05594-0","volume":"615","author":"T Brevini","year":"2023","unstructured":"Brevini T, Maes M, Webb GJ, et al. FXR inhibition may protect from SARS-CoV-2 Infection by reducing ACE2. Nature. 2023;615(7950):134\u201342. https:\/\/doi.org\/10.1038\/s41586-022-05594-0.","journal-title":"Nature"},{"key":"8913_CR3","doi-asserted-by":"publisher","unstructured":"Kovell LC, Ahmed HM, Misra S, et al. US Hypertension management guidelines: a review of the recent past and recommendations for the future. J Am Heart Assoc. 2015;4. https:\/\/doi.org\/10.1161\/JAHA.115.002315.","DOI":"10.1161\/JAHA.115.002315"},{"key":"8913_CR4","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.tcm.2019.05.003","volume":"30","author":"JM Flack","year":"2020","unstructured":"Flack JM, Adekola B. Blood pressure and the new ACC\/AHA Hypertension guidelines. Trends Cardiovasc Med. 2020;30:160\u20134. https:\/\/doi.org\/10.1016\/j.tcm.2019.05.003.","journal-title":"Trends Cardiovasc Med"},{"key":"8913_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nature02145","volume":"426","author":"W Li","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature. 2003;426:450\u20134. https:\/\/doi.org\/10.1038\/nature02145","journal-title":"Nature"},{"key":"8913_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","volume":"63","author":"X Xu","year":"2020","unstructured":"Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457\u201360. https:\/\/doi.org\/10.1007\/s11427-020-1637-5.","journal-title":"Sci China Life Sci"},{"key":"8913_CR7","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461.","journal-title":"Circulation"},{"key":"8913_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364\u201374. https:\/\/doi.org\/10.1007\/s11427-020-1643-8.","journal-title":"Sci China Life Sci"},{"key":"8913_CR9","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","volume":"7","author":"A Grover","year":"2021","unstructured":"Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2021;7:148\u201357. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa064.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"20","key":"8913_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [published correction appears in JAMA. 2020;323(20):2098]. JAMA. 2020;323(20):2052\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6775.","journal-title":"JAMA"},{"key":"8913_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with Hypertension. Emerg Microbes Infect. 2020;9:757\u201360. https:\/\/doi.org\/10.1080\/22221751.2020.1746200.","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"8913_CR12","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with Hypertension hospitalized with COVID-19 [published correction appears in Circ Res. 2020;127(6):e147. Rohit, Loomba [corrected to Loomba, Rohit]]. Circ Res. 2020;126(12):1671\u201381. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317134.","journal-title":"Circ Res"},{"key":"8913_CR13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with Hypertension hospitalized for coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5:825\u201330. https:\/\/doi.org\/10.1001\/jamacardio.2020.1624.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"8913_CR14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jch.14101","volume":"23","author":"AZ Bauer","year":"2021","unstructured":"Bauer AZ, Gore R, Sama SR, et al. Hypertension, medications, and risk of severe COVID-19: a Massachusetts community-based observational study. J Clin Hypertens (Greenwich). 2021;23(1):21\u20137. https:\/\/doi.org\/10.1111\/jch.14101.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"8913_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3.","journal-title":"The Lancet"},{"issue":"1","key":"8913_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41421-022-00468-1","volume":"8","author":"Y Ling","year":"2022","unstructured":"Ling Y, Lu G, Liu F, et al. The Omicron BA.2.2.1 subvariant drove the wave of SARS-CoV-2 outbreak in Shanghai during spring 2022. Cell Discov. 2022;8(1):97. https:\/\/doi.org\/10.1038\/s41421-022-00468-1. Published 2022 Sep 27.","journal-title":"Cell Discov"},{"issue":"5","key":"8913_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jinf.2022.07.027","volume":"85","author":"Y Ao","year":"2022","unstructured":"Ao Y, Li J, Wei Z, et al. Clinical and virological characteristics of SARS-CoV-2 Omicron BA.2.2 variant outbreaks during April to May, 2022, Shanghai, China. J Infect. 2022;85(5):573\u2013607. https:\/\/doi.org\/10.1016\/j.jinf.2022.07.027.","journal-title":"J Infect"},{"key":"8913_CR18","doi-asserted-by":"publisher","unstructured":"Vaduganathan M, Vardeny O, Michel T et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653\u20139. https:\/\/doi.org\/10.1056\/NEJMsr2005760","DOI":"10.1056\/NEJMsr2005760"},{"key":"8913_CR19","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1161\/HYPERTENSIONAHA.120.15082","volume":"75","author":"AHJ Danser","year":"2020","unstructured":"Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75:1382\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15082.","journal-title":"Hypertension"},{"key":"8913_CR20","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/EHJCVP\/PVAA030","volume":"6","author":"A Battistoni","year":"2020","unstructured":"Battistoni A, Volpe M. Might renin-angiotensin systemblockers play a role in the COVID-19 pandemic? Eur Heart J Cardiovasc Pharmacother. 2020;6:248\u201351. https:\/\/doi.org\/10.1093\/EHJCVP\/PVAA030.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"8913_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.120.15143","volume":"76","author":"G Yang","year":"2020","unstructured":"Yang G, Tan Z, Zhou L, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus Infection, inflammatory status, and clinical outcomes in patients with COVID-19 and Hypertension: a single-center retrospective study. Hypertension. 2020;76:51\u20138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15143.","journal-title":"Hypertension"},{"key":"8913_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/jmv.25770","volume":"92","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92:791\u20136. https:\/\/doi.org\/10.1002\/jmv.25770.","journal-title":"J Med Virol"},{"key":"8913_CR23","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.cca.2020.06.009","volume":"509","author":"J Bao","year":"2020","unstructured":"Bao J, Li C, Zhang K, et al. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19. Clin Chim Acta. 2020;509:180\u201394. https:\/\/doi.org\/10.1016\/j.cca.2020.06.009.","journal-title":"Clin Chim Acta"},{"key":"8913_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10753-020-01337-3","volume":"44","author":"M Iwasaki","year":"2021","unstructured":"Iwasaki M, Saito J, Zhao H, et al. Inflammation triggered by sars-cov-2 and ace2 augment drives multiple organ failure of severe covid-19: molecular mechanisms and implications. Inflammation. 2021;44:13\u201334. https:\/\/doi.org\/10.1007\/s10753-020-01337-3.","journal-title":"Inflammation"},{"key":"8913_CR25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the \u2018Cytokine Storm\u2019\u2019 in COVID-19\u2019. J Infect. 2020;80:607\u201313. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.037.","journal-title":"J Infect"},{"key":"8913_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jamda.2020.09.004","volume":"21","author":"B Genet","year":"2020","unstructured":"Genet B, Vidal JS, Cohen A, et al. COVID-19 in-hospital mortality and use of renin-angiotensin system blockers in geriatrics patients. J Am Med Dir Assoc. 2020;21:1539\u201345. https:\/\/doi.org\/10.1016\/j.jamda.2020.09.004.","journal-title":"J Am Med Dir Assoc"},{"key":"8913_CR27","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1001\/jama.2020.2648","volume":"323","author":"Z Wu","year":"2020","unstructured":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for Disease control and prevention. JAMA. 2020;323:1239\u201342. https:\/\/doi.org\/10.1001\/jama.2020.2648.","journal-title":"JAMA"},{"key":"8913_CR28","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with Hypertension and Diabetes Mellitus at increased risk for COVID-19 Infection? The Lancet Respiratory. 2020;8:e21. https:\/\/doi.org\/10.1016\/S2213.","journal-title":"The Lancet Respiratory"},{"key":"8913_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497\u2013506. https:\/\/doi.org\/10.1016\/S0140-6736(20)30183-5.","journal-title":"The Lancet"},{"key":"8913_CR30","unstructured":"Who. Severity of Disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 Infection. In: World Health Organization; 2022."},{"issue":"4","key":"8913_CR31","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.bj.2022.04.006","volume":"45","author":"KK Chen","year":"2022","unstructured":"Chen KK, Tsung-Ning Huang D, Huang LM. SARS-CoV-2 variants - evolution, spike protein, and vaccines. Biomed J. 2022;45(4):573\u20139. https:\/\/doi.org\/10.1016\/j.bj.2022.04.006.","journal-title":"Biomed J"},{"issue":"23","key":"8913_CR32","doi-asserted-by":"publisher","first-page":"11031","DOI":"10.1111\/jcmm.17051","volume":"25","author":"HJ Zhao","year":"2021","unstructured":"Zhao HJ, Li Y, Wang DY, Yuan HT. ARB might be superior to ACEI for treatment of hypertensive COVID-19 patients. J Cell Mol Med. 2021;25(23):11031\u20134. https:\/\/doi.org\/10.1111\/jcmm.17051.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"8913_CR33","doi-asserted-by":"publisher","first-page":"11810","DOI":"10.1038\/s41598-023-38838-8","volume":"13","author":"S Hamada","year":"2023","unstructured":"Hamada S, Suzuki T, Tokuda Y, et al. Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19. Sci Rep. 2023;13(1):11810. https:\/\/doi.org\/10.1038\/s41598-023-38838-8. Published 2023 Jul 21.","journal-title":"Sci Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08913-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08913-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T03:03:59Z","timestamp":1703041439000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08913-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8913"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08913-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Shanghai Fourth People\u2019s hospital (No. 2022-074-001) and reported in the Chinese Clinical Trial Register (No. ChiCTR2200061804).The Ethics Committee of the Shanghai Fourth People\u2019s hospital waived the need of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"882"}}